Clinical Research Directory

Inclusion Criteria: * Participants must have a diagnosis of dementia. * They must be prescribed one medication indicated for dementia symptoms such as Aricept, Namenda, or Donepezil, and be prescribed at least one additional medication. * Participants must have an active study partner that is willing to be enrolled into the study and willing to receive messages and alerts from the HiDO-ALZ system if medications are missed. The study partner must also agree to complete surveys about the participant's ongoing health. * Participants must be willing to allow research staff to enter their homes to install the HiDO-ALZ device and to complete study activities. The participant's medications will be reviewed by the UCD pharmacist prior to randomization. If a participant has contraindicated medication(s), this medication will need to be removed or justified by the prescribing clinician prior to randomization. The research team and HiDO staff will work with the UCD pharmacist and prescribing clinician to resolve contraindicated medications prior to randomization. If a resolution is not possible, the participant will not be enrolled. •MoCA score of 15 to 22 or previous MMSE score of 21 to 26 within the last 6 months. If no test is available, the participants will be given a MoCA test after signing consent to confirm eligibility. Exclusion Criteria * The inability to demonstrate capacity to consent or assent as determined by the Capacity Assessment Checklist. * Individuals who do not have a study partner/caregiver (e.g., spouse, adult child) to complete questionnaires. * Participants with MoCA scores below 15 will be excluded as they may not be able to use the device independently. * Participants who are unable or unwilling to complete the cognitive testing or unwilling to complete the blood tests.